Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to determine in patients receiving intravenous (IV) antibiotic(s), if giving oral vancomycin therapy will prevent C. difficile-associated infection (commonly called CDI). Oral vancomycin is an antibiotic that is commonly used to treat CDI. The investigators want to study if using this drug can prevent the development of CDI while you are in the hospital receiving IV antibiotics. The key risk factors for developing CDI are age and IV antibiotic therapy. CDI is an infection in your colon caused by an organism called Clostridium difficile (or C. diff for short) that causes diarrhea. Up to 12% of hospital-acquired infections have been reported to be CDI. It can lead to longer hospital stays and more costs associated with the hospital stay.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04241744
Study type Interventional
Source Creighton University
Contact
Status Withdrawn
Phase Phase 4
Start date October 29, 2019
Completion date January 13, 2020

See also
  Status Clinical Trial Phase
Completed NCT03462459 - Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Completed NCT05508607 - Precision Antimicrobial STewardship for Clostridioides DIfficile Prevention
Completed NCT03497806 - Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiotaâ„¢ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection Phase 2
Completed NCT03621657 - The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation Phase 2
Recruiting NCT04100603 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection
Completed NCT03788434 - Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 2